Spero Therapeutics, Inc. (SPRO)
1.19
-0.07
(-5.56%)
USD |
NASDAQ |
Oct 02, 16:00
1.195
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Price to Book Value : 1.565 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.565 |
| October 01, 2026 | 1.657 |
| September 30, 2026 | 1.592 |
| September 29, 2026 | 1.578 |
| September 28, 2026 | 1.565 |
| September 25, 2026 | 1.618 |
| September 24, 2026 | 1.644 |
| September 23, 2026 | 1.657 |
| September 22, 2026 | 1.789 |
| September 21, 2026 | 1.500 |
| September 18, 2026 | 1.486 |
| September 17, 2026 | 1.473 |
| September 16, 2026 | 1.460 |
| September 15, 2026 | 1.486 |
| September 14, 2026 | 1.500 |
| September 11, 2026 | 1.486 |
| September 10, 2026 | 1.473 |
| September 09, 2026 | 1.539 |
| September 08, 2026 | 1.565 |
| September 04, 2026 | 1.592 |
| September 03, 2026 | 1.605 |
| September 02, 2026 | 1.605 |
| September 01, 2026 | 1.578 |
| August 31, 2026 | 1.605 |
| August 28, 2026 | 1.578 |
| Date | Value |
|---|---|
| August 27, 2026 | 1.592 |
| August 26, 2026 | 1.605 |
| August 25, 2026 | 1.618 |
| August 24, 2026 | 1.598 |
| August 21, 2026 | 1.605 |
| August 20, 2026 | 1.592 |
| August 19, 2026 | 1.618 |
| August 18, 2026 | 1.578 |
| August 17, 2026 | 1.565 |
| August 14, 2026 | 1.618 |
| August 13, 2026 | 1.631 |
| August 12, 2026 | 1.565 |
| August 11, 2026 | 1.618 |
| August 10, 2026 | 1.618 |
| August 07, 2026 | 1.657 |
| August 06, 2026 | 1.671 |
| August 05, 2026 | 1.657 |
| August 04, 2026 | 1.618 |
| August 03, 2026 | 1.513 |
| July 31, 2026 | 1.539 |
| July 30, 2026 | 1.578 |
| July 29, 2026 | 1.565 |
| July 28, 2026 | 1.572 |
| July 27, 2026 | 1.552 |
| July 24, 2026 | 1.565 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 21.85 |
| Fortress Biotech, Inc. | 0.412 |
| Kura Oncology, Inc. | 19.56 |
| ACADIA Pharmaceuticals, Inc. | 2.628 |
| Alnylam Pharmaceuticals, Inc. | 21.70 |
Price to Book Value Related Metrics
| PE Ratio | 10.91 |
| PS Ratio | 1.599 |
| Price to Free Cash Flow | 3.508 |
| Price | 1.19 |
| Earnings Yield | 9.17% |
| Market Cap | 69.19M |
| Operating PE Ratio | 26.64 |
| Normalized PE Ratio | 10.21 |